Summary
The anthracycline derivatives Adriamycin and 4-epirubicin are used to prevent recurrent tumors after transurethral resection of superficial bladder tumors. Both drugs are instilled intravesically. The present report describes the results of two multicenter, prospective, randomized phase III studies carried out by the EORTC GU Group. In protocol 30790, after a mean follow-up period of 26.6 months, the recurrence rate for 165 patients treated with Adriamycin was 0.29 and the tumor rate was 0.74. For 156 patients treated with Epodyl, the recurrence rate was 0.29 and the tumor rate was 0.57. This difference was not statistically significant. For 70 patients who received transurethral resection alone, the recurrence rate was 0.65 and the tumor rate, 2.04. In protocol 30863, patients with good prognostic factors were treated with one single instillation of 4-epirubicin versus sterile water. After a mean follow-up period of 16 months, in 190 patients treated with 4-epirubicin the recurrence rate was 0.20 and the tumor rate was 0.35; in 196 patients treated with sterile water, the recurrence rate was 0.37 and the tumor rate was 0.65 (P=0.0001). Adriamycin and 4-epirubicin were efficacious, and severe side effects were not enountered. The superiority of Adriamycin over Epodyl could not be proven.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Banks MD, et al. (1977) Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 118: 758
Bouffioux CH (1985) Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given? In: Superficial bladder cancer. (EORTC monograph 2, part B) Alan R. Liss, New York, p 47
Calais da Silva, et al. (1988) Intravesical chemoresection with 4-epidoxorubicin in patients with superficial bladder tumors. Eur Urol 14: 207
Herr HW, Laudone VP, Whitmore WF Jr (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138: 1363
Kurth KH (1984) Adjuvant chemotherapy of superficial transitional cell bladder carcinoma. J Urol 132: 258
Kurth KH, Senge T, Ay R, Sylvester R, Ten Kate F, De Pauw M, the EORTC GU Group (1989) Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: final analysis of a randomized trial. J Urol 141: 333A
Kurth KH, et al. (1992) Phase I and phase II study in patients with carcinoma in situ of the bladder with epirubicin. In: Uro-Oncology. Alan R. Liss, New York (in press)
Meijden APM van der, Debruyne FMJ (1988) Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short term courses or maintenance therapy. Urology [Suppl] 31: 26
Niijima T, et al. (1983) Randomized clinical trials on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol [Suppl] 11: S79
Oosterlinck W, Kurth KH, Schröder F, Van Aubel O, Marechal JM, Newling D, Sylvester R, Hammond B, the EORTC GU Group (1990) TUR only versus epirubicin in single primary or recurrent Ta, T1 papillary carcinoma of the bladder. Preliminary results of EORTC protocol 30863. Eur Urol 18 [Suppl 1]: 216
Soloway MS, Masters S (1980) Urothelial susceptibility to tumor cell implantation. Cancer 46: 1158
Soloway MS, Jordan AM, Murphy WM (1989) Rationale for intravesical chemotherapy and prophylaxis of superficial transitional cell carcinoma. In: BCG in superficial bladder cancer. Alan R, Liss, New York, p 215
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
van der Meijden, A.P.M., Kurth, KH., Oosterlinck, W. et al. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother. Pharmacol. 30 (Suppl 1), S95–S98 (1992). https://doi.org/10.1007/BF00686952
Issue Date:
DOI: https://doi.org/10.1007/BF00686952